Braidwell LP Makes New Investment in GH Research PLC $GHRS

Key Points

• Braidwell LP acquired 207,240 shares of GH Research in the second quarter, worth approximately $5.6 million and representing a 0.30% stake. Institutional investors collectively own 56.9% of the company.
• GH Research shares opened at $28.07, up 2.6%, with a market capitalization of about $1.93 billion. The company reported a quarterly loss of $0.23 per share, beating analysts’ expected loss of $0.29.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $45.00; individual targets range as high as $65.00.

Braidwell LP acquired a new stake in GH Research PLC (NASDAQ:GHRS - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 207,240 shares of the company's stock, valued at approximately $5,571,000. Braidwell LP owned 0.30% of GH Research at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Royal Bank of Canada raised its stake in shares of GH Research by 43.1% during the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company's stock worth $36,000 after purchasing an additional 780 shares during the period. Troluce Capital Advisors LLC increased its holdings in GH Research by 165.4% during the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock worth $13,926,000 after buying an additional 617,260 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in GH Research during the first quarter worth about $290,000. North Star Investment Management Corp. bought a new stake in GH Research in the first quarter worth about $31,000. Finally, Avoro Capital Advisors LLC bought a new stake in GH Research in the fourth quarter worth about $22,860,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Stock Up 2.6%

NASDAQ GHRS opened at $28.07 on Thursday. The company has a market cap of $1.93 billion, a PE ratio of -28.07 and a beta of 1.27. GH Research PLC has a 52 week low of $11.83 and a 52 week high of $31.44. The firm's 50-day simple moving average is $28.10 and its two-hundred day simple moving average is $21.84.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.06. As a group, equities research analysts anticipate that GH Research PLC will post -1.2 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating on shares of GH Research in a research note on Monday, August 10th. Cantor Fitzgerald raised their price target on shares of GH Research from $35.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Zacks Research raised shares of GH Research from a "strong sell" rating to a "hold" rating in a report on Thursday, August 13th. Citigroup reiterated an "outperform" rating on shares of GH Research in a research note on Friday, May 15th. Finally, New Street Research set a $65.00 price objective on GH Research in a report on Monday, August 10th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $45.00.

GH Research Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

Want to see what other hedge funds are holding GHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GH Research PLC (NASDAQ:GHRS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source